Reuters logo
BRIEF-‍Siamab Therapeutics and Boehringer Ingelheim announce strategic cancer immunology discovery collaboration​
October 4, 2017 / 11:11 AM / in 15 days

BRIEF-‍Siamab Therapeutics and Boehringer Ingelheim announce strategic cancer immunology discovery collaboration​

Oct 4 (Reuters) -

* ‍Siamab Therapeutics and Boehringer Ingelheim announce strategic cancer immunology discovery collaboration​

* Siamab Therapeutics​ - collaboration with ‍boehringer Ingelheim​ to develop antibody therapeutics targeting multiple solid tumors

* ‍Siamab Therapeutics​ - ‍under terms of agreement, siamab will use its platform to discover ‍tumor associated carbohydrate antigens​ selective targeting antibodies​

* ‍Siamab Therapeutics​ - ‍financial terms of agreement are not being disclosed​

* ‍Siamab - ‍Boehringer will have option to conduct further engineering, development and commercialization of anti-taca antibodies resulting from collaboration​ Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below